InvestmentAug 13, 2026, 05:01 PM
MapLight Therapeutics Secures $150M Private Placement
AI Summary
MapLight Therapeutics, Inc. announced a $150 million private placement of common stock and pre-funded warrants with institutional investors, expected to close on August 14, 2026. This financing, combined with existing cash, is projected to extend the company's cash runway through 2028, funding key clinical programs. The company also reported positive Phase 2 results for ML-007C-MA in schizophrenia and provided updates on other clinical trials and Q2 2026 financial results, including a net loss of $60.2 million.
Key Highlights
- Secured $150 million gross proceeds from a private placement of common stock and pre-funded warrants.
- Sold 9,197,887 shares of common stock at $11.38 per share and 3,983,168 pre-funded warrants.
- Cash, cash equivalents, and investments totaled $351.3 million as of June 30, 2026.
- Combined with financing, cash runway is extended through 2028, covering VISTA and ZEPHYR-2 readouts.
- Reported positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia, meeting primary endpoint.
- ML-007C-MA Phase 2 VISTA trial for ADP enrollment ongoing, with topline results expected H2 2027.
- Q2 2026 R&D expenses increased to $53.4 million from $26.8 million in Q2 2025.
- Reported a net loss of $60.2 million for Q2 2026, compared to $29.8 million in Q2 2025.
Price Impact
More from MPLT